Research programme: Nanozyme D - Cenyx Biotech
Alternative Names: Nanozyme-DLatest Information Update: 08 Jan 2023
At a glance
- Originator Cenyx Biotech
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 08 Jan 2023 Early research in Unspecified in South Korea (unspecified route) before January 2023 (Cenyx Biotech pipeline, January 2023)